Members of the nuclear receptor superfamily play key roles in a host of physiologic and pathologic processes from embryogenesis to cancer. Some members, including the retinoic acid receptor (RAR), are activated by ligand binding but are unaffected in their subcellular distribution, which is predominantly nuclear. In contrast, several members of the steroid receptor family, including the glucocorticoid receptor, are cytoplasmic and only translocate to the nucleus after ligand binding. We have constructed chimeras between RAR and glucocorticoid receptor that selectively respond to RAR agonists but display cytoplasmic localization in the absence of ligand. These chimeric receptors manifest both nuclear translocation and gene activation functions in response to physiological concentrations of RAR ligands. The ability to achieve regulated subcellular trafficking with a heterologous ligand binding domain has implications both for current models of receptor translocation and for structural-functional conservation of ligand binding domains broadly across the receptor superfamily. When coupled to the green fluorescent protein, chimeric receptors offer a powerful new tool to 1) study mechanisms of steroid receptor translocation, 2) detect dynamic and graded distributions of ligands in complex microenvironments such as embryos, and 3) screen for novel ligands of "orphan" receptors in vivo.
the cytoplasm and moves rapidly into the nucleus in response to hormone stimulation. Other members of the nuclear receptor superfamily are either complex in their intracellular distributions (e.g. mineralocorticoid receptor (1), progesterone receptor (2, 3) , androgen receptor (4) , and dioxin receptor (5)) or are found primarily in the nucleus (e.g. estrogen receptor (6) , thyroid hormone receptor (see Refs. 7 and 8) , and retinoic acid receptor (RAR; see Refs. 7 and 8)). The recent characterization of functional GFP fusions with the steroid/nuclear receptors allows study of real time movement for these molecules within living cells (9) . The unliganded GFP-GR is found completely in the cytoplasm, whereas the hormone-activated receptor is located almost exclusively in the nucleus shortly after hormone activation (9 -11) . Because nuclear translocation by this intrinsically fluorescent receptor is quite dramatic and easily monitored in real time in vivo, it can provide a straightforward methodology to detect physiological concentrations of receptor ligand in the cellular environment.
The availability of chimeric proteins with the nuclear/cytoplasmic translocation properties of GR, and the ligand responsiveness of the nuclear receptors, would provide a powerful translocation assay for nuclear receptor ligands and potentially for novel analogues, as well. Many chimeric receptors have been described (e.g. see Ref. 12) , but these fusions have been characterized exclusively in terms of their gene activation potential. We describe here a GR-RAR chimeric protein 2 that resides primarily in the cytoplasm of untreated cells but manifests complete nuclear translocation when cells are induced with the normal RAR ligand, all-trans-retinoic acid. This chimera forms the basis for a new, in vivo translocation assay for nuclear receptor ligands and has important implications for mechanisms of receptor subcellular trafficking.
EXPERIMENTAL PROCEDURES
Cell Lines and Transfections-The 1471.1 cell line was used for all studies (13) . Cells were maintained in DMEM with 10% characterized fetal calf serum (FCS; Hyclone Laboratories, Logan, UT), L-glutamine, and antibiotics. For transient transfections, 2 ϫ 10 7 cells were resuspended in cold DMEM (without serum) with the indicated plasmids and incubated on ice for 1 min. Electroporations were done in a BTX Electro Square Porator (San Diego, CA) at 140 V, 3 pulses, and 10-ms pulse length followed by a 10-min recovery on ice. Cells were then plated and allowed to recover overnight in complete media.
Receptor Chimeras-Sequences 3Ј to the coding region for helix 1 (H1) of the LBD of GFP-tagged rat GR (pCI-nGFP-C656G; see Fig. 1 ) were replaced by a multiple cloning site (MCS) polylinker as follows. A polymerase chain reaction fragment was generated to contain GR sequences including a unique SphI site and extending through the end of the LBD H1 with the MCS fused at the 3Ј end, using the primers AAAAGAGCAGTGGAAGGA (5Ј) and GGTCTAGAATTCCC-TCGAGA-GGCCTCGCGAAACAGAGCTATCATATCC (3Ј). The polymerase chain reaction product was restricted with SphI and XbaI and inserted at the corresponding SphI and XbaI sites in pCI-nGFP-C656G. A version tagged with EGFP was also made by cloning the NheI filled in BspEI fragment from EGFP-C1 (CLONTECH) between the NheI and filled in BssHII sites of the LBD-deleted C656G GR. The LBD-deleted C656G * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ Contributed equally to this work. 2 Patent pending on the GR-RAR chimera.
GR constructs were confirmed by sequencing. Different GR-RAR chimeras were generated by cloning portions of the LBD from a human RAR-␣ cDNA (gift from K. Ozato) in-frame into the MCS of LBD-deleted GR. The chimera shown in Fig. 1 was made by fusing the RAR-LBD, starting at the end of its H1 coding region (from amino acid 195) and extending through the end of the coding sequence and 300 bases of 3Ј untranslated region, to the end of the GR LBD H1 region. The RAR-LBD-containing fragment from FspI (filled in) to EcoRI was cloned between the XhoI (filled in) and the EcoRI sites of LBD-deleted C656G GR and was confirmed by sequencing.
Fluorescence Microscopy-For fluorescence microscopy, cells were electroporated with 2 g of GFP-GR-RAR, GFP-GR, or GFP-RAR. After electroporation, 1/24th of the cells were plated in each well of a 6-well dish onto a clean 1.5 glass coverslip in DMEM containing 10% charcoal/ dextran-treated FCS (Hyclone Laboratories, Logan, UT). The next day, cells were treated with the indicated ligand for 1 h, and cells on coverslips were rinsed with phosphate-buffered saline, inverted onto microscope slides, and immediately viewed on a Leica TCS SP scanning confocal microscope. GFP was excited with a 488-nm laser line supplied from an air-cooled argon laser. GFP emission was monitored between 505 and 590 nm with a pinhole setting of 1.0.
Assay of Receptor Activity-Cells were electroporated with 5 g of pLTRLuc (containing the mouse mammary tumor virus promoter) and 0.7 g of pCMV-␤-Gal with or without 10 g of the indicated receptor expression vector as described above. Cells were plated in duplicate in 100-mm dishes in DMEM containing 10% charcoal/dextran-treated FCS (as above) and allowed to recover overnight. The next day, cells were treated with the indicated ligand for 6 h. Luciferase and ␤-galactosidase were assayed as described (3) .
Co-immunoprecipitation Assays-Transfected cells were harvested at 36 -48 h and lysed in 300 l of HEM (20 mM Hepes, pH 7, 1 mM EDTA, 10% glycerol, 10 mM sodium molybdate) ϩ 0.5% Nonidet P-40 ϩ 2 mM dithiothreitol per 10 7 cells for 5 min at 4°C. A protease inhibitor mixture was also included. Nuclei were pelleted, and the cytoplasmic extract was precleared with blank protein G-Sepharose for 2 h at 4°C and then immunoadsorbed against protein G-Sepharose pre-loaded with anti-GFP antibody (monoclonal antibody 3E6; QBiogene) overnight at 4°C. Sepharose pellets were then washed with 3 ϫ 1 ml of HEM ϩ 50 mM NaCl ϩ 0.5% Tween 20, boiled in electrophoresis loading buffer, run on 4 -12% BisTris gradient gels (NuPage; Invitrogen), and blotted. Western blots were sequentially probed first with anti-HSP90 (monoclonal antibody H90 -10; gift from David Toft), then with anti-GFP (monoclonal antibody 11E5; QBiogene), and finally with anti-GR (antipeptide (amino acids 346 -367) polyclonal antibody PA1-511A; Affinity Bioreagents, Inc.).
RESULTS AND DISCUSSION
Our goal was to modify the LBD of GFP-GR in such a way that the unique cytoplasmic/nuclear translocation activity of GR would be maintained, but the modified chimera would respond to a nuclear receptor ligand. The development of such a system faces several potential problems. First, insofar as they are understood, the nuclear localization signals of GR are embedded within the LBD and the C-terminal region of the DNA binding domain (14) . Thus, complete replacement of the GR LBD might disrupt the regulated translocation signals we intend to utilize. Second, GR interacts (in the cytoplasm) with a complex array of chaperon proteins, including HSP90 and HSP70, and ligand-dependent displacement of these proteins is thought to be intimately involved in the translocation process (15) . Interaction domains critical for HSP90 binding are located within helix 1 of the GR LBD (16), and steroid binding also requires contacts between an LXXLL motif in helix 1 and The resulting fusion protein includes the last six amino acids of the RAR-LBD helix 1 (19, 20) , as well as the complete GR LBD helix 1 (inferred from the LBD structure of the progesterone receptor (22)). GR domains also included in the fusion are the heptapeptide element essential for HSP90 binding (16) and the putative LXXLL interaction motif (17) . N-term, Nterminal; DBD, DNA binding domain. hydrophobic residues in the ligand binding pocket of the LBD (17) . Available crystal structures (18 -25) , including that for progesterone receptor, which is most closely related to GR, indicate there is a high degree of overall structural conservation in the LBD of various steroid receptor family members. However, the nuclear receptor group (thyroid hormone receptor and RAR) does not interact with the chaperone proteins (26, 27) , at least in the "docking" capacity implicated in cytoplasmic retention for the steroid receptors. Furthermore, some of the hydrophobic "contacts" in the steroid binding pocket that are proposed to interact with the LXXLL motif (17) are not conserved between the LBD of GR and some of the nuclear receptors such as RAR. Thus, removal or alteration of the GR LBD could disrupt both the chaperone interaction domains and the nuclear localization signals in this region of the protein. Additionally, perturbing the interactions of the LXXLL motif with the LBD might also abrogate ligand-dependent translocation, because these interactions are important for steroid binding. With this perspective, GFP-GR-RAR fusions were generated, in which the GR LBD was replaced by the corresponding domain from RAR preserving the GR helix 1 region intact, and evaluated for transactivation potential and cellular distribution of the chimeric proteins. One chimera (referred to here as GR-RAR; see Fig. 1 ) was retinoid-regulated in both transactivation function and subcellular trafficking (see Fig. 2 and Fig. 3 ).
Ligand-dependent transactivation was tested in transient transfection assays with a mouse mammary tumor virus-luciferase reporter. The GR* parent construct used has an LBD point mutation that increases agonist (dexamethasone) sensitivity by 20-fold (28) over the endogenous cellular GR (Fig. 2 , compare Control with GR* for 1 nM Dex versus 100 nM Dex). GR-RAR is refractory to Dex but strongly activated by 100 nM all-trans-retinoic-acid (ATRA). Furthermore, no competition for cofactors ("squelching") by the chimera is observed when the endogenous cellular GR is induced by 100 nM Dex (Fig. 2 , GR* versus GR-RAR), because the GR-RAR chimera remains cytoplasmic in the presence of Dex (see below). Thus the chimeric protein behaves as a retinoic acid-dependent transactivator but is nonresponsive to GR agonists.
Subcellular trafficking was examined in response to ligands. Representative examples of results are shown in Fig. 3 ; in each case, essentially all of the transfected cells in culture responded uniformly in the same manner as the examples shown. The GR receptor is completely cytoplasmic in the absence of ligand and becomes exclusively nuclear in response to Dex (Fig. 3 , panels D and E) but is unaffected by ATRA (Fig. 3, panel F) . Wild-type RAR is always nuclear, as expected (Fig. 3, panels G-I) . GR-RAR is cytoplasmic in non-treated cells and remains cytoplasmic after Dex treatment (Fig. 3, panels A and B) but translocates to the nucleus with ATRA (Fig. 3, panel C) . That is, the GR-RAR chimera retains the cytoplasmic localization of ligandfree wild-type GR but translocates in response to the normal RAR ligand rather than GR agonists.
Xu et al. (16) suggest that a seven-residue region in helix 1 of the LBD is all that is required for stable HSP90 binding by GR and attribute the requirement for other sequences seen in earlier studies (e.g. see Refs. 29 and 30) to the necessity of D-F) , or GFP-RAR (panels G-I). Cells were treated for 1 h with medium containing only charcoalstripped serum (panels A, D, and G) , 100 nM dexamethasone (panels B, E, and H), or 100 nM ATRA (panels C, F, and I). In those examples where the subcellular distribution is nuclear (panels C, E, G, H, and I), the cell outline is indicated by a dashed white line. The cells shown in panels D and I are binucleate.
FIG. 4.
Interaction of cytoplasmic chimeric receptor with HSP90. Cytoplasmic extracts from cells transfected with GFP fusions to GR* or to GR-RAR or with native EGFP were immunoprecipitated (IP) using an anti-GFP monoclonal antibody separated on a 4 -12% gradient gel, blotted, and probed with anti-HSP90 antibody. About 0.5% of each extract used prior to IP was also run (load) for comparison. Blots were subsequently reprobed with anti-GFP and with anti-GR antibodies as a control to confirm uniformity in binding and recovery of immunoprecipitate. The anti-GFP antibody used for Western blotting (different from the IP antibody) reacted poorly with the GFP fusion proteins, which were undetectable in the load. Anti-GR was used as a second control for binding and recovery. Ig, immunoglobulin. maintaining a properly folded protein structure. Accordingly, the ability of the chimeric GR-RAR receptor to interact with HSP90 should be preserved, because the GR heptapeptide sequence is still present but in the context of a new LBD. Because the cytoplasmic interaction with HSP90 is thought to be critical for steroid binding and regulated translocation of the receptor (15) , it was of interest to determine whether the ability of the chimeric GR-RAR receptor to interact with HSP90 is retained. Cytoplasmic extracts from cells transfected with GR, the GR-RAR chimera fused to GFP, or with native EGFP were each immunoprecipitated with anti-GFP antibody, and the precipitates were probed for the presence of bound HSP90 (Fig. 4) . Both cytoplasmic GR and GR-RAR chimera interacted specifically with HSP90, whereas EGFP did not, suggesting that HSP90 interactions key to ligand-regulated translocation have indeed been conserved in the chimeric protein.
Availability of crystal structures for the LBD of several receptors has led to a compelling model for LBD structural rearrangements involved in ligand binding and coactivator interactions (18 -25) . In contrast, the receptor transitions responsible for intracellular trafficking are not well understood, and no general model exists to account for the subcellular distribution of the steroid/nuclear receptor superfamily. The GR-RAR chimera provides a new experimental paradigm to elucidate mechanisms of ligand-induced nuclear translocation. Simons and colleagues (17) identified an LXXLL motif in helix 1 of the GR LBD as critical for steroid binding. This motif contacts residues in helix 8 and 9 of the steroid binding pocket, acting as a "clasp" for the binding pocket. These investigators proposed an intramolecular "hinged pocket" model as the LBD molecular rearrangement involved in hormone binding. The helix 1 region from the GR LBD is intact in the GR-RAR chimera (Fig. 1) , although the steroid binding pocket itself has been switched. Furthermore, the amino acids in helix 8 and 9 proposed to make critical contacts with LXXLL based on considerations from the progesterone receptor LBD crystal structure (17, 22) are not well conserved between GR and RAR. Thus, a further examination of the hinged pocket model would seem to be warranted. The ability to swap LBDs and obtain novel ligand-regulated translocation has important implications for the structural requirements necessary to maintain ligand-mediated translocation and will serve as a valuable tool in elucidating how the ligand-induced structural transition is transmitted from the RAR-LBD to domains of the chimeric protein critical for translocation.
It is also evident from the present results that it should be feasible to easily generate similar chimeras using other receptor LBDs to identify new ligands and to detect ligand levels in situ. Such chimeras provide a ligand detection tool fundamentally distinct from existing techniques, which test receptor responses at the gene activation, or transcriptional, level. The approach described here tests directly for the ability of an LBD to induce translocation, and hence interactions with transcriptional coactivators, chromatin remodeling factors, etc., are unlikely to play a significant role.
For example, the GFP-coupled GR-RAR chimera provides the unique capability to directly see dynamic, temporospatial distributions of retinoids in real time, in live organisms. Retinoids are thought to function as "morphogens" in a number of developmental processes, but retinoic acid gradients have yet to be directly demonstrated. Localization efforts using retinoidresponsive promoters to drive reporter genes are inherently limited by the slow response and level of sensitivity to ligand (in co-cultures of reporter cells with tissue explants (31-33) ) or by their dependence on endogenous cellular receptors, cofactors, and the limitations of the particular transgenic promoters used (reporters assayed in genetically engineered animals (12, 32, 34) ). In contrast, the translocation-based assay is rapid (20 -30 min of exposure), is visualized directly in vivo, and is independent of the particular transcriptional milieu of the cell.
Screens for novel receptor ligands using transcriptional reporters are similarly limited, whereas the translocation assay with a GFP-tagged chimera requires no biochemical manipulations and allows rapid, direct visualization in living cells. Epifluorescent cellular imaging systems driven by artificial intelligence software can now automatically scan and quantify the subcellular distribution of fluorescent molecules in large numbers of living cell pools. These imaging systems, coupled with such a translocation assay, can be employed in high throughput screens for novel receptor ligands in vivo.
